>>Signaling Pathways>> GPCR/G protein>> Prostaglandin Receptor>>Tiaprost (Iliren)

Tiaprost (Iliren) (Synonyms: Iliren)

Catalog No.GC31445

티아프로스트(Iliren)는 프로스타글란딘 F2α입니다. (PGF2α) 유사체.

Products are for research use only. Not for human use. We do not sell to patients.

Tiaprost (Iliren) Chemical Structure

Cas No.: 71116-82-0

Size 가격 재고 수량
1mg
US$202.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Tiaprost is a prostaglandin F2α (PGF2α) analogue.

Plasma progesterone levels decrease sharply within 12 hours after the initial treatment with Tiaprost and within 24 hours reach levels at about 3.18 nM (1 ng/mL). Over the following days, progesterone levels remain either slightly above (cows 1, 3, 5 and 6) or below (cow 2) 3.18 nM. In cow 4, levels remain for 17 days above 3.18 nM and drop below this level thereafter. At term, all cows show the lowest recorded progesterone levels (1 to 2 nM). Repeated luteolytic treatments with Tiaprost (cows 1 and 2) or estradio1 benzoate (cow 3) has no further influence on individual progesterone levels. Treatment with progesterone-releasing intravaginal device (PRID) does not significantly elevate progesterone plasma levels. Total estrogens in plasma remained in general unchanged[1].

[1]. Grunert E, et al. Delayed termination of third-trimester gestations in dairy cows after treatment with the PGF(2alpha)analog Tiaprost. Theriogenology. 1984 May;21(5):823-34.

리뷰

Review for Tiaprost (Iliren)

Average Rating: 5 ★★★★★ (Based on Reviews and 31 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Tiaprost (Iliren)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.